(NASDAQ: MAZE) Maze Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 61.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Maze Therapeutics's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast MAZE's revenue for 2025 to be $547,464,575, with the lowest MAZE revenue forecast at $547,464,575, and the highest MAZE revenue forecast at $547,464,575. On average, 1 Wall Street analysts forecast MAZE's revenue for 2027 to be $547,464,575, with the lowest MAZE revenue forecast at $547,464,575, and the highest MAZE revenue forecast at $547,464,575.
In 2028, MAZE is forecast to generate $2,768,856,835 in revenue, with the lowest revenue forecast at $547,464,575 and the highest revenue forecast at $4,990,249,094.